INTERCEPT (Investigating Novel Therapy to target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): a multi-arm, precision-based, recursive, platform trial

  • Wei, Andrew (Primary Chief Investigator (PCI))
  • DiNardo, Courtney (Chief Investigator (CI))
  • Roberts, Andrew W. (Chief Investigator (CI))
  • Daver, Naval (Chief Investigator (CI))
  • Reynolds, John (Chief Investigator (CI))
  • Blombery, Piers (Chief Investigator (CI))
  • Marlton, Paula (Chief Investigator (CI))
  • Curtis, David (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date1/07/21 → 30/06/25

Keywords

  • acute myeloid leukaemia (AML)
  • targeted therapy
  • myeloid leukaemia
  • clinical trial
  • drug resistance